{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:23:10Z","timestamp":1784794990235,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,11]]},"DOI":"10.7759\/cureus.89840","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:14:16Z","timestamp":1754957656000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Clinical and Imaging Parameters in Patients With Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Prospective Observational Study"],"prefix":"10.7759","author":[{"given":"Ekta","family":"Devi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishir K","family":"Chandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti  P","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara K","year":"2019","unstructured":"Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol. 2019, 32:385-94. 10.1097\/WCO.0000000000000694","journal-title":"Curr Opin Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon VA","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005, 202:473-7. 10.1084\/jem.20050304","journal-title":"J Exp Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters P","year":"2016","unstructured":"Waters P, Reindl M, Saiz A, et al.. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016, 87:1005-15. 10.1136\/jnnp-2015-312601","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader S","year":"2011","unstructured":"Mader S, Gredler V, Schanda K, et al.. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011, 8:184. 10.1186\/1742-2094-8-184","journal-title":"J Neuroinflammation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/2055217316675634","article-title":"Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India","volume":"2","author":"Pandit L","year":"2016","unstructured":"Pandit L, Sato DK, Mustafa S, et al.. Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. Mult Scler J Exp Transl Clin. 2016, 2:2055217316675634. 10.1177\/2055217316675634","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk DM","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al.. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015, 85:177-89. 10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, et al.. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol. 2023, 22:268-82. 10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius S","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020, 6:85. 10.1038\/s41572-020-0214-9","journal-title":"Nat Rev Dis Primers"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47565","article-title":"Patterns of adult neuromyelitis optica spectrum disorder patients compared to multiple sclerosis: a systematic review and meta-analysis","volume":"15","author":"Alqwaifly M","year":"2023","unstructured":"Alqwaifly M, Althobaiti AH, AlAibani NS, Banjar RZ, Alayed RS, Alsubaie SM, Alrashed AT. Patterns of adult neuromyelitis optica spectrum disorder patients compared to multiple sclerosis: a systematic review and meta-analysis. Cureus. 2023, 15:e47565. 10.7759\/cureus.47565","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD","volume":"95","author":"Duchow A","year":"2024","unstructured":"Duchow A, Bellmann-Strobl J, Friede T, et al.. Time to disability milestones and annualized relapse rates in NMOSD and MOGAD. Ann Neurol. 2024, 95:720-32. 10.1002\/ana.26858","journal-title":"Ann Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac480","article-title":"Clinical and MRI measures to identify non-acute MOG-antibody disease in adults","volume":"146","author":"Cortese R","year":"2023","unstructured":"Cortese R, Battaglini M, Prados F, et al.. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain. 2023, 146:2489-501. 10.1093\/brain\/awac480","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231156736","article-title":"Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey","volume":"29","author":"Nakamura M","year":"2023","unstructured":"Nakamura M, Ogawa R, Fujimori J, et al.. Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Mult Scler. 2023, 29:530-9. 10.1177\/13524585231156736","journal-title":"Mult Scler"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp V","year":"2021","unstructured":"Papp V, Magyari M, Aktas O, et al.. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021, 96:59-77. 10.1212\/WNL.0000000000011153","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12452-8","article-title":"Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis","volume":"271","author":"Arnett S","year":"2024","unstructured":"Arnett S, Chew SH, Leitner U, et al.. Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis. J Neurol. 2024, 271:4794-812. 10.1007\/s00415-024-12452-8","journal-title":"J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu T","year":"2005","unstructured":"Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005, 65:1479-82. 10.1212\/01.wnl.0000183151.19351.82","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.128559","article-title":"A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort","volume":"17","author":"Barhate KS","year":"2014","unstructured":"Barhate KS, Ganeshan M, Singhal BS. A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Ann Indian Acad Neurol. 2014, 17:77-81. 10.4103\/0972-2327.128559","journal-title":"Ann Indian Acad Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.33588\/rn.6505.2017037","article-title":"Neuromyelitis optica spectrum disorders: profile of a cohort according to the 2015 diagnostic criteria","volume":"65","author":"Uribe-San Martin R","year":"2017","unstructured":"Uribe-San Martin R, Ciampi E, Galilea A, et al.. Neuromyelitis optica spectrum disorders: profile of a cohort according to the 2015 diagnostic criteria. Rev Neurol. 2017, 65:193. 10.33588\/rn.6505.2017037","journal-title":"Rev Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/aian.aian_860_21","article-title":"Comparison of clinical and radiological features of aquaporin4 (AQP-4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) and anti myelin oligodendrocyte glycoprotein (anti-MOG) syndrome-our experience from Northwest India","volume":"25","author":"Jain RS","year":"2022","unstructured":"Jain RS, Jain D, Murarka S, et al.. Comparison of clinical and radiological features of aquaporin4 (AQP-4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) and anti myelin oligodendrocyte glycoprotein (anti-MOG) syndrome-our experience from Northwest India. Ann Indian Acad Neurol. 2022, 25:246-55. 10.4103\/aian.aian_860_21","journal-title":"Ann Indian Acad Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk DM","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-15. 10.1016\/S1474-4422(07)70216-8","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam DH","year":"2020","unstructured":"Whittam DH, Karthikeayan V, Gibbons E, et al.. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020, 267:3565-77. 10.1007\/s00415-020-10026-y","journal-title":"J Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum","volume":"20","author":"Uzawa A","year":"2024","unstructured":"Uzawa A, Oertel FC, Mori M, Paul F, Kuwabara S. NMOSD and MOGAD: an evolving disease spectrum. Nat Rev Neurol. 2024, 20:602-19. 10.1038\/s41582-024-01014-1","journal-title":"Nat Rev Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.158755","article-title":"Neuromyelitis optica and neuromyelitis optica spectrum disorder: natural history and long-term outcome, an Indian experience","volume":"6","author":"Jagtap SA","year":"2015","unstructured":"Jagtap SA, Mandliya A, Sarada C, Nair MD. Neuromyelitis optica and neuromyelitis optica spectrum disorder: natural history and long-term outcome, an Indian experience. J Neurosci Rural Pract. 2015, 6:331-5. 10.4103\/0976-3147.158755","journal-title":"J Neurosci Rural Pract"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.355118","article-title":"Neuromyelitis optica spectrum disorders in North Indian population: experience from a tertiary care center","volume":"70","author":"Sachdeva J","year":"2022","unstructured":"Sachdeva J, Goyal MK, Singh R, Kapila AT, Singh P, Saikia B, Lal V. Neuromyelitis optica spectrum disorders in North Indian population: experience from a tertiary care center. Neurol India. 2022, 70:1500-5. 10.4103\/0028-3886.355118","journal-title":"Neurol India"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4951491","article-title":"A longitudinal comparison of the recovery patterns of optic neuritis with MOG antibody-seropositive and AQP4 antibody-seropositive or -seronegative for both antibodies","volume":"2022","author":"Zhou L","year":"2022","unstructured":"Zhou L, Tan X, Wang L, Zhao X, Qiu W, Yang H. A longitudinal comparison of the recovery patterns of optic neuritis with MOG antibody-seropositive and AQP4 antibody-seropositive or -seronegative for both antibodies. J Ophthalmol. 2022, 2022:4951491. 10.1155\/2022\/4951491","journal-title":"J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius S","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, et al.. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012, 9:14. 10.1186\/1742-2094-9-14","journal-title":"J Neuroinflammation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/393079-comparison-of-clinical-and-imaging-parameters-in-patients-with-neuromyelitis-optica-spectrum-disorder-and-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-a-prospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:14:17Z","timestamp":1754957657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/393079-comparison-of-clinical-and-imaging-parameters-in-patients-with-neuromyelitis-optica-spectrum-disorder-and-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-a-prospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.89840","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,11]]}}}